Ibrutinib Interruption Tied to Worse Outcomes in CLL Ibrutinib Interruption Tied to Worse Outcomes in CLL

In a retrospective analysis, patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib had worse outcomes if the dosing was interrupted for any reason.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news